Will Dengue Vaccines Be Used in the Public Sector and if so, How? Findings from an 8-country Survey of Policymakers and Opinion Leaders

PLoS Neglected Tropical Diseases

Volumn 7, Issue 3, 2013, Pages

  Douglas, Don L ^a   DeRoeck, Denise A ^b   Mahoney, Richard T ^b   Wichmann, Ole ^c  

^a Janani   (India)

^b International Vaccine Institute   (South Korea)

^c ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE;

AGE; ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DENGUE; DRUG COST; ECONOMIC ASPECT; GOVERNMENT; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION CONTROL; MORTALITY; POLICY; SAFETY; SEMI STRUCTURED INTERVIEW; SYMPTOM; VACCINATION; VACCINE PRODUCTION;

EID: 84875987524     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002127     Document Type: Article

References (23)

1. Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, et al. (2012) Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS NTD 6 (8) (): e1760.
2. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, et al. (2010) Dengue: A continuing global threat. Nat Rev Microbiol 8 (12 Supple) (): S7-16.
3. WHO, Global Alert and Response (GAR). Impact of dengue. Available from: http://www.who.int/csr/disease/dengue/impact/en/. Accessed January 30, 2013.
4. Lozano R, Naghavi M, Foreman K, Lim S, Kenji Shibuya, et al. (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2095-128.
5. Batson A, Glass S, Seiguer E (2003) Economics of vaccines: from vaccine candidate to commercialized product. In: Bloom LP, Editor. The Vaccine Book. London: Academic Press. pp. 345-370.
6. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, et al. (2011) From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29: 7229-41.
7. Wright PF, Durbin AP, Whitehead SS, Ikizler MR, Henderson S, et al. (2009) Phase 1 trial of the dengue virus type 4 vaccine candidate rden4{delta}30-4995 in healthy adult volunteers. Am J Trop Med Hyg 81 (5) (): 834-41.
8. Osorio JE, Huang CY, Kinney RM, Stinchcomb DT, (2011) Development of denvax: A chimeric dengue-2 pdk-53-based tetravalent vaccine for protection against dengue fever. Vaccine 29 (42) (): 7251-60.
9. Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH, (2011) The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 29 (42) (): 7267-75.
10. Simpson E, Wittet S, Bonilla J, Gamazina K, Cooley L, et al. (2007) Use of formative research in developing a knowledge translation approach to rotavirus vaccine introduction in development countries. BMC Public Health 7: 281.
11. DeRoeck D, Clemens JD, Nyamete A, Mahoney RT, (2005) Policymakers' views regarding the introduction of vaccines against typhoid fever, shigellosis and cholera in Asia. Vaccine 23: 2762-74.
12. Teixeira MG, Costa MCN, Barreto F, Barreto ML, (2009) Dengue: twenty-five years since reemergence in Brazil. Cad Saúde Pública, Rio de Janeiro 25 Sup 1: S7-18.
13. Murphy BR, Whitehead SS, (2011) Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 29: 587-619.
14. DeRoeck D, Deen J, Clemens JD, (2003) Policymakers' views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four Southeast Asian countries. Vaccine 22 (1) (): 121-9.
15. Jodar L, LaForce FM, Ceccarini C, Aguado T, Granoff DM, (2003) Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 361 (9372) (): 1902-4.
16. Frash C, Preziosi MP, LaForce FM, (2012) Development of a group A meningococcal conjugate vaccine, MenAfriVac. Hum Vaccin Immunother 8 (6) (): 715-24.
17. Munira SL, Fritzen SA, (2007) What influences government adoption of vaccines in developing countries? A policy process analysis. Soc Science Med 65: 1751-1764.
18. Haas M, Ashton T, Blum K, Christiansen T, Conis E, et al. (2009) Drugs, sex, money and power: An HPV vaccine case study. Health Policy 92: 288-295.
19. Kimman TG, Boot HJ, Berbers GAM, Vermeer-de Bondt PE, de Wit GA, et al. (2006) Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs. Vaccine 24: 4769-4778.
20. Hajjeh RA, Privor-Dumm L, Edmond K, O'Loughlin R, Shetty S, et al. (2010) Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience. Vaccine 28: 7123-7129.
21. Shearer JC, Stack ML, Richmond MR, Bear AP, Hajjeh RA, et al. (2010) Accelerating policy decisions to adopt Haemophilus influenzae Type b vaccine: a global, multivariable analysis. PLoS Med 7 (3) (): e10000249.
22. Wenger JD, DiFabio JL, Landaverde JM, Levine OS, Gaafar T, (2000) Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four 'newly adopting' countries. Vaccine 18: 736-642.
23. Burchett HED, Mounier-Jack S, Griffiths UK, Mills AJ, (2012) National decision-making on adopting new vaccines: a systematic review. Health Policy Plan 27 Suppl 2: ii62-ii76.